Business
Foghorn Therapeutics Inc.: We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.
Revenue increased 36.8% to $30.9M, while Net loss narrowed 14.2% to $74.3M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $30.9MWatch
- Profitability — Net loss $74.3MWatch
- Cash generation — Free cash flow −$86.1MNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Foghorn Therapeutics Inc. reports it. History and quarterly detail are in the app.
- The$30.9M
Leadership changes
From Foghorn Therapeutics Inc.'s own filings, the day they're filed.
- Ryan D. Maynard · Chief Financial Officer · appointmenteff. 2026-02-23
- Jeff Sacher · Chief Financial Officer · appointmenteff. 2025-12-03
- Stuart Duty · director · appointmenteff. 2025-05-01
Latest filings
- 8-K · Company announcement2026-10-01
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-24
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Foghorn Therapeutics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.